Piper Sandler analyst Matt O’Brien lowered the firm’s price target on Globus Medical (GMED) to $80 from $100 and keeps an Overweight rating on the shares. The firm notes the company reported Q1 results that saw it miss meaningfully on the top-and-bottom lines. There were a number of factors including soft enabling-tech deal closures, and supply chain disruption. Piper understands investor frustration here, especially given the integration appeared to have been going well to this point, but the firm believes many of these headwinds are transient and it has seen this organization recover from other bumps in the past.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GMED:
- Globus Medical price target lowered to $77 from $88 at BTIG
- Globus Medical Faces Challenges: Hold Rating Amid Revenue Miss and Cautious Outlook
- Cautious Hold Rating on Globus Medical Amid Supply Chain Challenges and Nevro Acquisition Uncertainty
- Globus Medical Reports Q1 2025 Financial Results
- Globus Medical’s Strategic NVRO Acquisition and Recovery Signs Support Buy Rating Despite Short-term Challenges
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue